Smalt Capital • Pharma Santé Développement
FranceWho owns Smalt Capital • Pharma Santé Développement?
Smalt Capital • Pharma Santé Développement is a French Healthcare company, now owned by Giropharm, which acquired it in 2024 from Societe Generale Capital Partenaires, SOFIPACA - Groupe Crédit Agricole and Smalt Capital.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
- ·Fully exited in 2024 to Giropharm.
- ·Average hold across 3 realized cycles: 7 years.
Ownership history
3 ownership periods · co-invest detected
Societe Generale Capital Partenaires sold Pharma Santé Développement Groupe to Giropharm in 2024 after 7 years.
Smalt Capital sold Pharma Santé Développement Groupe to Giropharm in 2024 after 7 years.
SOFIPACA - Groupe Crédit Agricole sold Pharma Santé Développement Groupe to Giropharm in 2024 after 7 years.
More from Smalt Capital
Other portfolio companies in the same fund.
More PE-backed in Healthcare
Comparable healthcare deals from other GPs.
US
Questions
Who owns Smalt Capital • Pharma Santé Développement?
Smalt Capital • Pharma Santé Développement is now owned by Giropharm, which acquired it in 2024 from Societe Generale Capital Partenaires, SOFIPACA - Groupe Crédit Agricole and Smalt Capital.
When did Giropharm acquire Smalt Capital • Pharma Santé Développement?
Giropharm acquired Smalt Capital • Pharma Santé Développement in 2024, buying from Societe Generale Capital Partenaires, SOFIPACA - Groupe Crédit Agricole and Smalt Capital.
Who did Smalt Capital • Pharma Santé Développement sell to?
Societe Generale Capital Partenaires, SOFIPACA - Groupe Crédit Agricole and Smalt Capital sold Smalt Capital • Pharma Santé Développement to Giropharm in 2024 (Trade Sale).
Who has owned Smalt Capital • Pharma Santé Développement over time?
Smalt Capital • Pharma Santé Développement has been through 3 private-equity ownership periods: Societe Generale Capital Partenaires · via SGCP Evergreen (balance sheet) · 2017–2024 · sold to Giropharm · (Trade Sale); SOFIPACA - Groupe Crédit Agricole · via SOFIPACA Evergreen · 2017–2024 · sold to Giropharm · (Trade Sale); Smalt Capital · via Smalt Capital · 2017–2024 · sold to Giropharm · (Trade Sale).